Amplia Therapeutics Featured in Biotech Daily

Release Highlights:

• Amplia Therapeutics, under the leadership of CEO Dr. Chris Burns, is focused on developing its lead compound, AMP945, a focal adhesion kinase (FAK) inhibitor. This compound targets fibrosis, enhancing the effectiveness of chemotherapy in treating difficult cancers such as pancreatic and ovarian cancer by removing the protective shields around tumors and rendering them more susceptible to treatment.
• The company is advancing its clinical trials, including a two-phase open-label trial named Accent, which combines AMP945 with standard chemotherapy for advanced pancreatic cancer. Early results from a Phase Ib trial showed promising outcomes, with partial responses in six patients and disease stabilization in the rest, leading to the current Phase IIa trial. Interim data from this trial are expected by September 2024.
• Financially, Amplia has bolstered its resources through a recent USD 4.27 million rights offer, bringing its cash reserves to approximately USD 5 million, sufficient to fund ongoing trials. The company’s shares, supported by institutional investors like Platinum Investment Management and Pengana Capital, have seen fluctuations but reflect a commitment to advancing innovative cancer therapies developed locally in Australia.